Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

4(44%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_3

33%

Ph phase_1

44%

Ph phase_2

22%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

4(44.4%)

Phase 2Efficacy & side effects

2(22.2%)

Phase 3Large-scale testing

3(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Completed(2)

Terminated(2)

Other(1)

Detailed Status

Active, not recruiting4

Completed2

Withdrawn2

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 14 (44.4%)

Phase 22 (22.2%)

Phase 33 (33.3%)

Trials by Status

unknown111%

active_not_recruiting444%

completed222%

withdrawn222%

Recent Activity

4 active trials

Showing 5 of 9

active_not_recruitingphase_3

A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer

NCT07386938

withdrawnphase_3

Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.

NCT06884254

active_not_recruitingphase_3

Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer

NCT05802225

active_not_recruitingphase_2

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.

NCT03161353

active_not_recruitingphase_1

Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man

NCT05825781

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT07386938Phase 3

A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer

Active Not Recruiting

NCT06884254Phase 3

Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.

Withdrawn

NCT05802225Phase 3

Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer

Active Not Recruiting

NCT03161353Phase 2

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.

Active Not Recruiting

NCT05825781Phase 1

Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man

Active Not Recruiting

NCT05323981Phase 1

Comparison of Pharmacokinetics and Safety of HS627(2 Specifications) Versus PERJETA With a Single Injection

Completed

NCT05738993Phase 1

A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers

Unknown

NCT04820439Phase 1

Pharmacokinetic Study of Recombinant Monoclonal Antibody Against Human Epidermal Growth Factor Receptor Injection

Completed

NCT03058939Phase 2

Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer

Withdrawn

All 9 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 9